Jim Cramer's 'Mad Money' Recap: Don't Bet Against This Market
at The Street - Tue Jun 17, 7:31PM CDT
The market reacted correctly to the continued tensions in Iraq and the effect on oil, Cramer said.
Final Glance: Biotechnology companies
AP - Tue Jun 17, 5:03PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
How Much Does This Failure Hurt Celgene?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Tue Jun 17, 4:30PM CDT
Celgene 's Vidaza, which began facing U.S. generic competition in September of 2013, just can't seem to catch a break. First there was the generic competition -- which dropped sales by 27% year-over-year last quarter to $148 million. And more...
Celgene's Pomalyst Data at European Hematology Association Shows Promise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 17, 12:40PM CDT
Celgene (CELG) presented data from a retrospective analysis of a phase III study on Pomalyst in the MM indication.
Midday Glance: Biotechnology companies
AP - Tue Jun 17, 12:27PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Early Glance: Biotechnology companies
AP - Tue Jun 17, 9:39AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Up 32%: Time to Buy Bluebird Bio?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Mon Jun 16, 5:35PM CDT
Bluebird bio shareholders had a great day today, with the stock up 32% on some early stage data for LentiGlobin from its HGB-205 study examining the drug as a treatment for beta-thalassemia major. Two patients in the trial have gone off blood...
Celgene's Vidaza Disappoints in Phase III Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 16, 5:10PM CDT
Celgene (CELG) has suffered a setback in its efforts to expand the label of Vidaza.
Agios Presents Data on AG-221 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 16, 4:21PM CDT
Agios Pharmaceuticals, Inc. (AGIO) announced new clinical data from the ongoing phase I study on candidate, AG-221, among patients suffering from IDH2 mutant positive hematologic malignancies.
2 Surging Biotechs with Links to Celgene
Todd Campbell, The Motley Fool - Motley Fool - Mon Jun 16, 1:03PM CDT
Celgene is sharing its experience and opening its wallet to a slate of fledgling biotech companies in a bid to lock-up the next generation of game-changing therapies. Agios and bluebird bio are two of those companies and each reported news...
Better Stock Today Challenge: Energy Transfer Partners vs. Celgene
Joel South and David Williamson, The Motley Fool - Motley Fool - Mon Jun 16, 12:00PM CDT
In the spirit of World Cup competition, we're holding our own tournament in search of the Better Stock Today. We're pitting 32 companies against each other and you, the reader, will determine the winner. Energy Transfer Partners takes on Celgene...
Better Stock Today: Celgene vs. American Express
Tyler Riggs and David Williamson, The Motley Fool - Motley Fool - Sat Jun 14, 1:18PM CDT
In the spirit of World Cup competition, we're holding our own tournament in search of the Better Stock Today. We're pitting 32 companies against each other, and you, the reader, will determine the winner. Celgene takes on American Express for...
Is Gene Therapy Medicine's Next Big Thing?
Todd Campbell, The Motley Fool - Motley Fool - Sat Jun 14, 12:05PM CDT
Bluebird Bio is a small company with big ideas. The clinical stage biotechnology company is researching novel treatments that seek to insert missing genes into patient stem cells. The science behind Bluebird's approach is so compelling that ...
Retrospective Analysis of Overall Survival Adjusting for Patient Crossover in Phase III Study of POMALYST(R)/IMNOVID(R) (Pomalidomide) in Previously Treated Multiple Myeloma Presented at EHA
Business Wire - Sat Jun 14, 11:30AM CDT
Celgene International Sarl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG) today announced that a retrospective analysis of MM-003, the Company's phase III study of pomalidomide plus low-dose dexamethasone compared with high-dose dexamethasone in patients with refractory multiple myeloma who have failed therapy with both bortezomib and lenalidomide, administered either alone or in combination, were presented at the 19th European Hematology Association annual congress. Pomalidomide is marketed as POMALYST(R) in the United States and IMNOVID(R) in the European Union.
Results from Phase III Study (AML-001) of VIDAZA(R) (Azacitidine for Injection) in Acute Myeloid Leukemia Presented at EHA
Business Wire - Sat Jun 14, 7:58AM CDT
Celgene International Sarl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that results from AML-001, its phase III study of VIDAZA(R) (azacitidine for injection) compared to conventional care regimens (CCR) in elderly subjects with newly-diagnosed acute myeloid leukemia (AML - >30% blasts) were presented in a late-breaking abstract oral session at the 19th European Hematology Association annual congress. The study was presented by Pr. Herve Dombret of the Hopital Saint-Louis in Paris, France.
Studies Presented at 19th European Hematology Association Annual Congress Evaluate Activin Receptor Ligand Trap Programs in Beta-Thalassemia
Business Wire - Sat Jun 14, 2:00AM CDT
Celgene Corporation (NASDAQ:CELG) and Acceleron Pharma Inc. (NASDAQ:XLRN) today announced interim data from two studies of candidates from the companies' joint development program in beta-thalassemia. The data presented at the 19th European Hematology Association (EHA) annual congress show activity for two programs, sotatercept and ACE-536, in patients with both transfusion dependent and non-transfusion dependent beta-thalassemia. There is currently no drug approved to treat beta-thalassemia. Both sotatercept and ACE-536 have been granted orphan drug designation for beta-thalassemia by the United States Food and Drug Administration (FDA).
Down 9%: Is OncoMed a Bad News Buy?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Fri Jun 13, 6:05PM CDT
OncoMed shareholders had a rough day, with potential issues with mild-to-moderate bone-related adverse events causing a halt in a phase 1 trial for two of the company's drugs. The big question, of course, is whether this makes for an attractive...
Analysis of Health-Related Quality of Life Measures from the MM-020/IFM 07-01 (FIRST(R)) Trial Presented at EHA Annual Congress
Business Wire - Fri Jun 13, 4:44PM CDT
Celgene International Sarl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that an analysis of health-related quality of life measures (HRQOL) from FIRST(R) (Frontline Investigation of Lenalidomide + Dexamethasone Versus Standard Thalidomide), its phase III study (MM-020/IFM 07-01) of REVLIMID(R) (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma (NDMM) ineligible for stem cell transplant was presented during the 19th European Hematology Association annual congress.